Evoq Remedies Ltd
₹ 7.31
0.00%
22 Nov
- close price
About
Incorporated in 2010, EVOQ Remedies
Ltd is engaged in the trading of pharmaceuticals formulation and allied products[1]
Key Points
- Market Cap ₹ 18.2 Cr.
- Current Price ₹ 7.31
- High / Low ₹ 19.4 / 7.21
- Stock P/E 40.4
- Book Value ₹ 18.6
- Dividend Yield 0.00 %
- ROCE 1.91 %
- ROE 1.80 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.39 times its book value
- Debtor days have improved from 339 to 157 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.50% over past five years.
- Promoter holding is low: 11.2%
- Company has a low return on equity of 5.18% over last 3 years.
- Company has high debtors of 157 days.
- Working capital days have increased from 1,291 days to 2,645 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | |
3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | |
Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 |
OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% |
0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 |
Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | |
0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | |
EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | -26% |
TTM: | -80% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 114% |
3 Years: | -15% |
TTM: | -72% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | 5% |
Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 |
Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 |
0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | |
2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | |
Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | |
Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 |
Cash Flows
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
0.01 | -0.02 | 0.03 | -26.43 | -4.35 | 5.32 | |
0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | |
0.00 | 0.00 | 0.00 | 29.49 | 1.42 | -5.34 | |
Net Cash Flow | 0.01 | -0.02 | 0.03 | 3.06 | -2.94 | -0.03 |
Ratios
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 |
Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 |
Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 |
Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 |
Working Capital Days | 1.12 | 1.21 | 26.23 | 614.06 | 612.39 | 2,645.12 |
ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Certificate under Regulation 74(5) of the SEBI (Depository and Participant) Regulations, 2018
-
Announcement Under Regulation 30 - General Announcement
1 Oct - Appointment of Aesha Shah and resignation of Pranav Vajani.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1 Oct - Appointment of Aesha Shah and resignation of Pranav Vajani.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
1 Oct - Appointment of Aesha Shah and resignation of Pranav Vajani.
-
Board Meeting Outcome for Outcome Under Regulation 30 Of SEBI (Listing Obligations And Disclosure
Requirements) Regulations, 2015
1 Oct - Appointment of Aesha Shah and resignation of Pranav Vajani.
Business Overview:[1][2]
Company is in the business of marketing, trading, and distribution of a wide range of pharmaceutical formulation products. Apart from this, the company also deals in trading of active pharmaceutical ingredients, Nutraceutical, Ayurvedic, and Herbal Products